Purpose of review The complexity of modern insulin-based therapy for type I and type II diabetes mellitus and the risks associated with excursions in blood-glucose concentration (hyperglycemia and hypoglycemia) have motivated the development of 'smart insulin' technologies (glucose-responsive insulin, GRI). Such analogs or delivery systems are entities that provide insulin activity proportional to the glycemic state of the patient without external monitoring by the patient or healthcare provider. The present review describes the relevant historical background to modern GRI technologies and highlights three distinct approaches: coupling of continuous glucose monitoring (CGM) to deliver devices (algorithm-based 'closed-loop' systems), glucoseresponsive polymer encapsulation of insulin, and molecular modification of insulin itself.
INTRODUCTION
Insulin replacement therapy is integral to the treatment of type I diabetes (T1DM) and often required in the treatment of type II diabetes (T2DM). These distinct diseases are respectively caused by an absolute or relative lack of insulin [1] . Insulin initiates the uptake of glucose within peripheral tissues by binding to its molecular target, the insulin receptor [2] . This receptor tyrosine kinase in turn activates a complex set of intracellular signaling processes [3] leading to the translocation of glucose transporter GLUT4 to the cell surface [4] . Regulated secretion of insulin by pancreatic b cells in response to increased interstitial glucose levels ordinarily enables the blood-glucose level (BGL) to be maintained within a narrow range, which in healthy individuals lies between 80 and 120 mg/dl (4.4-5.6 mM) with fasting values between 80 and 100 mg/dl [5] .
Unlike pancreatic secretion of insulin, standard pharmacological administration of insulin is not regulated by an endogenous feedback mechanism. Even with carefully designed dosing regimens and use of modern insulin products (i.e., engineered basal and rapid-acting insulin analogs) and even in the context of strict dietary and lifestyle adherence by patients, patients with diabetes often experience periods of hyperglycemia or hypoglycemia [6] . The chronic health risks associated with elevated mean glycemia (microvascular and macrovascular disease, renal disease, retinopathy, and neuropathy) are insidious relative to the dramatic presentation of acute metabolic decompensation (diabetic ketoacidosis in T1DM and hyperglycemic coma in T2DM) or the immediate signs and symptoms of hypoglycemia (adrenergic and neuroglycopenic effects leading to anxiety, tremulousness, and altered mental status leading in severe cases to coma) [7, 8] . Further, such acute events can trigger adverse cardiovascular events in the setting of preexisting vascular disease [9] , and repeated severe hypoglycemic episodes can cause cumulative damage to the brain with cognitive decline [10] . For these reasons, avoidance of hypoglycemia often limits individual hemoglobin A 1c goals (an integrated indicator of mean glycemia over 3 months) and the rigor of current insulin treatment regimens.
A long-standing goal has been development of insulin delivery systems that would co-optimize treatment of hyperglycemia and prevention of hypoglycemia. Such systems would, like endogenous pancreatic b cells, provide insulin action proportionate to the glycemic state of the patient. Accordingly, 'smart insulin' systems [broadly designated glucose-responsive insulin (GRI)] have attracted the attention of the research community for four decades [11, 12] . Such systems are defined as a class of insulin-delivery devices or insulin formulations that provide insulin activity commensurate with the metabolic needs of the patient. Because of the clinical considerations summarized above, the development of GRI technology has been a strategic priority of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [13] and the Juvenile Diabetes Research Fund (JDRF) [14] .
Our definition of GRI is based on the conceptual goal of glucose-regulated delivery rather than any particular mechanical or molecular embodiment.
Because this goal is shared by closed-loop delivery systems (i.e., the 'artificial pancreas', or AP, as based on CGM-coupled insulin pumps [15] ) and because such systems are near regulatory approval, they provide a starting point for our discussion. This perspective may be unconventional, but highlights clinical goals as our ultimate objective. In the coming decade closed-loop systems are likely to provide the gold standard with respect to which the efficacy and safety of 'smart' molecular strategies will be evaluated.
With this in mind, GRIs may be broadly classified as follows: algorithm-based mechanical GRI systems [15] in accordance with the above definition; polymer-based systems, in which insulin is encapsulated within a glucose-responsive polymeric matrix-based vesicle or hydrogel [16] ; or molecular GRI analog systems, which involve the introduction of a glucose-sensitive motif to the insulin molecule or its formulation, in either case conferring glucoseresponsive changes to the bioavailability or activity of the hormone [17] .
MECHANICAL GLUCOSE-RESPONSIVE INSULINS
Mechanical GRI systems have three components: a CGM providing real-time measurement of the interstitial glucose concentration, an insulin pump capable of receiving data from the CGM, and a computer-encoded algorithm that predicts the appropriate dose of insulin for subcutaneous injection [18, 19] . Optimization of such systems has led to efforts to enhance the accuracy and precision of CGMs and the robustness of the control algorithms. Because changes in interstitial glucose concentration lag by 20 min behind changes in BGL, because the insulin analog (once injected) may require 20-40 min for absorption into the blood stream, and because the hormone (once in the blood steam) may exert biological effects lasting 3-4 h, a critical feature of modern algorithms is prediction of future trends in BGL. The robustness of such predictive algorithms is likely to be enhanced by the development of 'ultra-fast' pump insulin analog formulations that minimize any delay in subcutaneous absorption and in the duration of targetcell signaling, once the insulin receptor is engaged [20] .
Advances in engineering over the past decade have led to the creation of compact devices in which CGMs are integrated within algorithm-controlled insulin pumps capable of precise adjustments in subcutaneous delivery rate [21] . Further, through analysis of clinical data and implementation of rapid signal-processing techniques, hierarchical
KEY POINTS
Although strict glycemic control is beneficial to patients with T1DM and in a subset of patients with T2DM, aggressive glycemic targets increase the risk of hypoglycemia, which has severe acute and longterm sequelae.
Glucose-responsive insulin (GRI) technologies represent a class of insulin-delivery devices or insulin formulations that provide insulin activity commensurate with the metabolic needs of the patient, effectively limiting hyperglycemia while simultaneously preventing hypoglycemic episodes.
Three major classes of GRIs have been developed: mechanical GRIs, which constitute continuous glucose monitors and insulin pumps integrated by hierarchical control algorithms; polymer-based GRIs in which insulin is encapsulated within a glucose-sensitive polymeric matrix; and molecular GRIs, in which the insulin molecule or its formulation have intrinsic glucoseresponsive activity.
algorithms that optimize glycemic control while prioritizing patient safety have been developed [20] [21] [22] [23] Intraperitoneal delivery of insulin may also offer advantages within closed-loop systems. Intraperitoneal delivery leads to ultra-rapid absorption and, like native pancreatic secretion, provides first-pass treatment of the liver. These features have led to the development of intraperitoneal infusion (IPI) devices [46, 47] as implanted and refillable pumps [48] . Despite their theoretical advantages and longterm reservoirs (up to 3 months), regulatory approval of IPIs in the United States has been withheld because of their susceptibility to catheter occlusion [49] . Such occlusions are in part inflammatory, provoked by formation of immunogenic and proinflammatory amyloid fibrils [50, 51] . In addition, fibrillation of insulin within the pump reservoir or catheter alters the flow properties of the solution and inactivates the hormone. Occlusive events limited the feasibility of routine IPI delivery in an otherwise encouraging clinical trial at U.S. Veterans Administration hospitals [52] . Nonetheless, long-term experience with intraperitoneal insulin pumps has been documented in Montpellier, FR with use of a special surfactant-stabilized U-400 insulin formation (Insuplant; Sanofi); periodic inhospital alkaline washes of the implanted reservoir are required to remove any fibrils or amyloidogenic seeds [49] .
The challenge of insulin degradation in pumps, whether external [53] or implanted [50] , may be addressed by development of ultra-stable, fibrillation-resistant insulin analogs. Two classes of insulin analogs have been shown to be refractory to fibrillation: single-chain insulins (SCIs) containing a foreshortened C domain (Fig. 1A ) [54] and twochain insulin analogs containing an engineered noncanonical disulfide bridge between the A and B chains [55] (Fig. 1B) . In each case the altered topology (connectivity) of the polypeptide is thought to be incompatible with regular cross-b assembly, the general structural mechanism underlying formation of amyloid [56] [57] [58] . Although such analogs have not been tested clinically, insertion of a noncanonical cystine is associated in rat studies with anomalously prolonged duration of activity on intravenous bolus injection [55] ; this would be an unfavorable feature of a pump insulin.
POLYMER AND MATRIX-BASED GLUCOSE-RESPONSIVE INSULINS
Polymer-or matrix-based GRI systems rely on sequestration of native or derivatized insulin molecules within a matrix suitable for subcutaneous injection. The matrix is designed to sense ambient glucose concentrations and release a proportional amount of insulin for systemic absorption. Three classes of glucose-sensitive motifs permit glucosedependent insulin sequestration: glucose-binding proteins (GBPs), a class that includes lectins like concanavalin A (ConA); glucose oxidase (GoD), an enzyme that catalyzes oxidation of glucose to gluconic acid with release of a proton (hence lowering the pH); and phenylboronic acid (PBA; Fig. 2 ), which forms reversible ester linkages with diolcontaining molecules, including glucose itself (Table 1) .
Brownlee and Cerami created the first model GRI system: glycosylated insulin complexed with ConA [11, 12] . This complex was intended to sequester insulin in the subcutaneous space during normoglycemia and release the hormone during hyperglycemia via competition with ambient glucose molecules. Although the strategy was successful in vitro, competitive setpoint was above typical hyperglycemic concentrations [66] . Later studies suggested that the immunogenicity and mitogenicity of ConA would impair clinical feasibility [64, 65] .
Advances in materials science have allowed development of polymer-based GRI systems. In such systems, insulin is encapsulated within polymer matrices as a 'smart' subcutaneous depot. Polymeric FIGURE 1. Ribbon model of the structure of ultra-stable insulin analogs. (a) Single chain insulin (SCI) contains the native A-domain (dark gray) and B-domain (light gray) and the three native disulfide linkages (yellow) of insulin. In addition, SCI analogs contain a foreshortened 'C-domain' (6-8 amino acids in length; orange) that connects the C-terminal strand of the B-domain (green) to the N-terminus of the A-domain. This domain dampens the conformational fluctuations of the molecule, thus increasing its thermodynamic stability and rendering it resistant to fibrillation [54] . (b) 4SS-insulin is a two-chain insulin analog (A-chain, dark gray, B-chain, light gray) that contains an engineered fourth disulfide linkage (red asterisk) between the A-and B-chains in addition to its three native disulfide linkages (yellow). The analog was reported to be resistant to fibrillation and have increased temperature stability [55] . FIGURE 2. Schematic of phenylboronic acid-monosaccharide complexation. Phenylboronic acid (PBA) comprises an aryl ring containing a boronic acid substituent group. When the boronic acid moiety is ionized to phenylboronate, the group may form reversible ester bonds with cis-diols, including those found on monosaccharides [59] . The pK a of unmodified PBA is 8.0 and it has an affinity for glucose of approximately 10 mM. Both of these properties may be modulated by introducing electronwithdrawing substituents to the aryl ring (red circle marked with 'X') [60] . A variety of groups, including nitro-, fluoro-, carboxyl, and sulfone groups have been shown to lower pK a of PBA to below physiological pH 7.4, affinities of these derivatives for glucose range from 8 to 14 mM [17] .
vesicles (polymerosomes) and microparticles or nanoparticles encapsulate insulin in a controlled subcutaneous environment that may mitigate foreign-body reactions or immune responses (Fig. 3A) [88, 89] . Such nanosystems are more amenable to fine tuning than is ConA complexation (Fig. 4A) .
Polymer-based GRIs can employ a variety of encapsulation chemistries. These include polyethylene glycol (PEG), poly-N-vinyl-pyrrolidone, and succinyl-amidophenyl-glucopyranoside [16, [91] [92] [93] or designed biomolecules such as modified peptides or lipids [94 & ,95 & ]. Although the matrices are impermeable to insulin during normoglycemic or hypoglycemic conditions, their permeability may increase as a result of structural changes that cause swelling or increased water solubility of the polymer in response to an increase in interstitial glucose concentration (Fig. 3B) . To this end, molecular glucose sensors (GBPs, GoD, and PBA) have been incorporated into such polymer scaffolds.
Several strategies have been tested to incorporate glucose sensors into polymer-based GRIs. These include insulin-encapsulating particles composed of matrices co-derivatized with PBA or other boronic acids [87, (Fig. 3C) .
GoD-based polymerosomes were recently employed by Yu et al. [74 && ] to encapsulate insulin in self-assembling polymersomes composed of PEG and polystyrene (as modified with 2-nitroimmidazole through a thioether linker). In this elegant scheme, local hypoxia induced by GoD activity promoted reduction of 2-nitroimmidazole into the more hydrophilic 2-aminoimmidazole by subcutaneous reductases, causing the encapsulating polymer to swell and become more water-permeable. The thioester linker served a dual purpose: to scavenge H 2 O 2 (a byproduct of GoD activity) and in so doing, through conversion of the thioester to a [84] Interaction not specific to glucose [85] Limited translational value Can degrade [17] Coupled to insulin for coinjection with polyols PBA polyol co-derivative insulin [17] Coupled to insulin via fattyacyl linkers [86] Co-polymerized with diolcontaining molecules in polymeric matrices [87] GRI, glucose-responsive insulin.
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sulfone, further increase the permeability of the matrix. After in-vitro confirmation of the mechanism of action, the polymersomes were integrated with cross-linked hyaluronic acid microneedle arrays for painless transcutaneous delivery [99] . This system was able to lower blood-glucose levels in diabetic mice within 60 min and maintain adequate glycemic control for approximately 5 hours. Critically, the system did not induce hypoglycemia in mice pretreated with insulin.
Challenges faced by polymer-based GRI technologies include limited particle stability [100] and suboptimal response rates: too slow in responding either to an increase or decrease in BGL (respectively leading to hyperglycemic or hypoglycemic excursions). Addressing these limitations has often yielded paradoxical results: sensitizing matrices to hyperglycemia, for example, can limit their ability to attenuate insulin release at low glucose levels. The latter problem can be exacerbated by matrix FIGURE 3 . Cartoon representation of polymer-based glucose-responsive insulins (GRIs). (a) Insulin is encapsulated within a polymeric matrix in large implants, transdermal patches, or microparticles or nanoparticles. The native or derivatized insulin analog is typically sequestered within a water-containing cavity within the hydrophobic, water impermeable polymer matrix. Such matrices are compact during hypoglycemia or euglycemia, but swell during hypoglycemia to release sequestered insulin (b). Several different methods have been used to create glucose-responsive polymers (c). (Top panels c) PBA (green hexagon) and glucose have been incorporated into polymeric scaffolds to maintain the compactness of the matrix. This interaction is competitively disfavored as ambient glucose concentrations rise, causing the polymer to swell. (Middle panels, c) Immobilized or co-encapsulated glucose-binding proteins (GBPs; red shapes) have been used as agents that stabilize the compactness of polymeric matrices in a glucose-dependent fashion. (Bottom panels, c) Matrices that are sensitive to the byproducts of coencapsulated or immobilized GoD (red polygon), gluconic acid and H 2 O 2 , along with the resulting decrease in pH and local hypoxia, have been developed. Oftentimes, polymeric matrices will undergo conformational changes resulting from changes in the protonation state of components (blue circles, red lines) of the scaffold or from reactions that are catalyzed by the byproducts of GoD.
degradation, raising the risk of a severe hypoglycemic episode [76, 101 && ]. Several groups have addressed the above challenges by creating GRI systems with multiple and complementary molecular mechanisms of glucose sensing and response. An example is provided by the combination of GoD, pH-sensitive matrices, and PBA modifications of the matrix or encapsulated insulin itself [83, 102] . Such a nanotechnology may respond rapidly to GoD activity and also retard the release of insulin during normoglycemia through its interactions with diols in the polymer matrix [101 && ,103,104] . Variation in particle size and permeable surface area [105] and addition of multiple layers of polymeric matrix [100] have also been shown to modulate glucose-response rates. In several microgel and nanogel systems, insulin has been encapsulated in largely impermeable polymer matrices that contain only small patches (or 'pores') of glucose-responsive polymeric material. This strategy seeks to limit the maximal rate of glucose release (thus mitigating risk of extreme hypoglycemia) while maintaining a rapid response to hyperglycemia [76] .
An alternative strategy for polymer-based GRI systems exploits the self-regulatory capability of FIGURE 4 . Cartoon representation of derivatization of the insulin molecule in glucose-responsive insulin (GRI) technology. The insulin hormone comprises two polypeptide chains that are designated 'A' and 'B' and are connected by two disulfide linkages spanning residues A7 and B7 and A20 and B19. (a) Sites that have been modified in molecular GRI development have been highlighted in colors corresponding to GRI systems illustrated in boxes. Brownlee et al. created a molecular GRI by coupling mono-and disaccharides to the N-termini of one or both polypeptide chains of insulin. These analogs were bound to ConA (red star) before administration. ConA was expected to sequester the insulin in the subcutaneous space during euglycemic conditions (left, a) and allow it to liberated by competitive binding of ambient glucose (blue hexagons) during hyperglycemia (right, a) [11, 66] . (b) Kashyap et al. created a GRI system using the clinical analog insulin glargine. Glargine contains an addition of two arginine residues at the C-terminus of its B-chain and a substitution of Asn A21 for glycine [77] .
These modifications shift the isoelectric point of the protein to near physiological conditions causing it to form precipitates after subcutaneous injection. In this GRI system glargine was co-injected with glucose oxidase (GoD; red polygon), which was expected to lower the local pH by oxidizing glucose to gluconic acid at a rate proportional to the glycemic state of the patient increasing the solubility and, hence, the bioavailability of glargine. with PBA derivatives and demonstrated the ability of the analog to couple to diol-containing polymer carriers (orange rectangles with red circles) in a glucose-dependent fashion [17] . (d) The same group also derivatized residue B29 with a molecule containing a PBA and a polyol group (black lines with red circles) and demonstrated the ability of the analog to form multihexameric complexes in vitro that could dissociate in a glucose-dependent fashion [90] . (e) Most recently, Chou et al. created a GRI that contained a PBA derivative coupled via a fatty acyl linker (black, jagged line with green hexagon) to Lys B29 , it was hypothesized that this analog would bind to albumin (blue oval) under normoglycemic conditions and become liberated during hyperglycemia as free glucose complexed with the PBA molecule and decreased the affinity of the analog for albumin [86] . Although this analog did show glucose-responsiveness in a mouse model, glucose-dependent association or dissociation from albumin was not confirmed.
cadaveric pancreatic b cells or those cultured from pluripotent stem cells (SC-b) to create a glucoseresponsive system [106] . A major barrier to b-cell implantation is posed by the foreign-body response (FBR) [107] . Encapsulation in polymeric matrices has long been investigated as a means to isolate implanted cells from such tissue reactions at the injection site [108] . Although several studies have shown the ability of polymer-encapsulated SC-bs to provide glycemic control in immunosuppressed diabetic animals [109, 110] , the first example of a functional polymer-encapsulated SC-b GRI in an immunocompetent animal was shown by Vegas et al. [111 && ]. SC-bs were encapsulated in 1.5 mm microspheres composed of azole-modified alginate (triazolethiomorpholine dioxide, TMTD). This demonstrated that in mice with diabetes such particles maintained euglycemia with no hypoglycemic episodes for 150 days. Further, the particles elicited only limited immune activation and FBR as assessed by analysis of immunological molecules adsorbed to the surface of extracted particles and of fibrosis-associated biomolecular markers [112] . The large size of the implanted particles (relative to other polymer-based GRI devices) and the derivatization of the alginate matrix with imidazole were identified as key innovations [ 
MOLECULAR GLUCOSE-RESPONSIVE INSULINS
Molecular GRIs represent a novel class of molecules in which the insulin molecule or its formulation confers glucose-dependent activity or bioavailability. Present candidate technologies rely on sequestration of active insulin hormone within the subcutaneous space or within the bloodstream (as inactive complexes) with enhanced release or activation only during hyperglycemia. Although such strategies remain in the early stages of development, the potential convenience and cost-effectiveness of molecular GRIs make them an attractive target for future analog design. An early strategy employed an insulin-GoD fusion molecule [75] . A cysteine-based linkage was broken as the enzyme oxidized glucose. Although proof of principle was obtained in vitro, the low K m of GoD for glucose led to liberation of the hormone under hypoglycemic conditions [75] . In addition, the release of hydrogen peroxide by GoD (as a byproduct of glucose oxidation) could damage surrounding tissues via generation of reactive oxygen species (ROS). In an unrelated approach, GoDdependent changes in ambient pH were exploited by Kashyap et al. [114] to modulate the solubility (and hence bioavailability) of insulin glargine, the active component of Lantus. Because this basal analog is insoluble at neutral pH but soluble under acidic conditions, GoD-mediated acidification (via production of gluconic acid) was predicted to increase the bioavailability of the insulin analog [115] (Fig. 4B) . Although this mechanism-based approach showed promise in vitro and demonstrated some improvement in glycemic control in pilot animal studies, no comprehensive report has been published [77] .
PBA was first described in the context of a GRI system by Hoeg-Jensen et al. [17] . The group demonstrated that derivatives of PBA could be coupled to insulin without affecting its biological activity, in turn enabling the analog to bind diol-containing sequestering agents (Fig. 4C) . The investigators further demonstrated that insulin analogs co-derivatized with PBA and polyols could form glucosedependent multimeric complexes in vitro (Fig. 4D ) [90, 116] . Similar (glucose-independent) formation of multimeric association states has been engineered within insulin degludec, a basal acylated insulin [117] . To our knowledge, no in vivo results have been described.
Recent use of a PBA-based GRI was described by the Langer-Anderson groups at MIT [86] . This study employed an acylated insulin analog (detemir, the active compotent of Levemir; Novo-Nordisk). Insulin detemir contains a myristic acid coupled to a unique lysine (Lys B29 ), which mediates binding to serum albumin and so provides a long-lived circulating depot. The MIT groups sought to derivatize the acyl tag with PBA so that its affinity for albumin would be glucose-responsive (Fig. 4E) [86] . Although this goal was not achieved in vitro, several of the candidate GRI analogs nonetheless exhibited glucose-responsive biological activity in a peritoneal glucose-infusion assay in mice. Molecular mechanisms underlying these provocative findings were not defined.
A new avenue for molecular GRI design may be opened by recent crystallographic studies of insulin bound to fragments of the insulin receptor ectodomain [2, 118] . Such studies have revealed a major change in the conformation of insulin on receptor binding (Fig. 5) . It may be possible to exploit this mechanism to design a glucose-dependent conformational switch such that binding of the modified insulin to the insulin receptor is impaired under conditions of hypoglycemia. This notion represents an active area of research.
CLINICAL SIGNIFICANCE AND CONCLUSION
The development of well tolerated and effective GRIs promises to enhance the health and quality of life of patients with T1DM and of patients with T2DM refractory to oral therapy. Strict glycemic control has been shown to retard or prevent microvascular complications in T1DM [119] and is likely to be beneficial in early stages of T2DM [120] [121] [122] . Aggressive insulin regimens nonetheless increase the acute and long-term risks of hypoglycemia [123] [124] [125] . Of particular concern as patients with T1DM live longer with current standards of medical management, recurring hypoglycemic episodes are associated with cognitive decline [8] .
In summary GRI technology offers the hope to provide intensive glycemic control without increased risk of hypoglycemia and with less burden on patients [7] . Although CGM-pump-based GRIs presently employ the most mature component technologies, recent innovations in matrix-based and molecular GRIs are elegant and suggest promising routes toward functional replacement of the pancreatic b cell. We anticipate continuing progress in the coming years. A controlled trial demonstrated that a bi-hormonal pancreas using standardized algorithms for dosing during exercise was able to reduce hypoglycemic episodes compared to manually adjusted artificial pancreas doses.
27. A large multicenter at-home study of bihormonal artificial pancreas that demonstrated the ability of the device to reduce periods of hypoglycemia and maintain target BGLs more efficiently than standard CGM insulin pumps.
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